This page shows the latest monalizumab news and features for those working in and with pharma, biotech and healthcare.
Innate Pharma’s lead candidate monalizumab – which is licensed by AstraZeneca – is heading for a pivotal phase 3 clinical trial. . ... The biotech – based in Marseille, France – will proceed into a phase 3 trial evaluating monalizumab in
Some of the proceeds will go towards Innate’s lead candidate monalizumab, an anti-NKG2A antibody which was licensed by AstraZeneca last year in a deal that included $100m in ... The French biotech licensed co-commercial rights to the drug at the same
It signed a deal with France’s Innate Pharma last October (centred on its anti-NKG2A antibody, monalizumab (IPH2201), and yesterday added an alliance with another French biotech, Transgene.
The main subject of the deal is Innate’s anti-NKG2A antibody, monalizumab (IPH2201), which targets a pathway thought to inhibit the activity of natural killer (NK) and cytotoxic T-cells ... for an option on anti-CD39 candidate IPH5201, which is in
Innate is also developing another checkpoint inhibitor - a CD94/NKG2A targeting antibody called monalizumab - as a monotherapy and in combination with AZ’s recently-approved PD-L1 inhibitor Imfinzi (durvalumab).
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
AstraZeneca. Anti-NKG2A antibody (monalizumab), IPH5201 (antibody targeting CD38) and Lumoxiti. #. for hairy cell leukaemia. Development &. commercialisation. collaboration. $307m. ViraTherapeutics/. Boehringer Ingelheim.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...